Photo: en.antaranews.com
Johnson & Johnson Launches "Dual Control" Campaign in Asia Pacific to Empower Patients
Johnson & Johnson has launched the 'Dual Control' campaign in Asia Pacific to empower patients with Crohn's disease and ulcerative colitis to manage their health and life aspirations effectively.
- Recent IBD research indicates that individuals with Crohn's disease face greater work impairment even during clinical remission compared to the general population, highlighting ongoing challenges in disease management.
- The 'Dual Control' campaign encourages patients to take proactive steps in their disease management, focusing on achieving endoscopic remission and improving overall quality of life.
- Johnson & Johnson, a leading biopharmaceutical company, aims to enhance patient engagement and support through this initiative, addressing the needs of those managing both Crohn's disease and ulcerative colitis.
Why It Matters
Empowering patients with Crohn's disease and ulcerative colitis is crucial in improving their quality of life and work productivity. As these conditions can lead to significant impairments even in remission, initiatives like Johnson & Johnson's campaign can lead to better health outcomes and overall life satisfaction.